pharmaphorum

OCTOBER 13, 2022

BeiGene is looking increasingly like it will become the leading challenger to AbbVie and Johnson & Johnson’s market-leading BTK inhibitor Imbruvica for cancer, after besting its rival in a clinical trial showdown. J&J recorded Imbruvica sales of $2.2 billion, a fall of 12.5%.

Side effects 52

Side effects Sales Marketing Competition 52

pharmaphorum

OCTOBER 10, 2022

Australian biotech Immutep’s LAG-3 checkpoint inhibitor eftilagimod alpha (efti) may not be the first drug in the class to reach the market, but is a strong contender and, according to at least one analyst, is on course for multibillion-dollar peak sales. month mPFS with Keytruda plus chemo, with fewer side effects.

Side effects 57

Side effects Sales Marketing FDA 57

pharmaphorum

DECEMBER 12, 2022

. “This is exciting news because existing treatments fail to improve platelet counts for as many as 30% of adults with chronic ITP,” commented said Catherine Broome of Georgetown Lombardi Cancer Centre in Washington DC, the trial’s lead investigator.

Side effects 52

Side effects Sales Competition Patients 52

pharmaphorum

AUGUST 5, 2022

Innovent is responsible for developing the drug in China, picking up exclusive marketing rights there, with Sanofi in line for up to €80 million in milestone payments as well as royalties on sales if it gets approved. It is being tested in a wide range of solid tumours and lymphoma, alone and in combination with other drugs.

Side effects 94

Side effects Marketing Pharma Medicine 94

Legacy MEDSearch

JUNE 15, 2023

Cala , the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease.

Patients 98

Patients Recruitment Pharmacology Side effects 98

Legacy MEDSearch

OCTOBER 25, 2023

Dr. Andrea Synowiec, a neurologist and headache specialist who serves as System Vice Chair of the Department of Neurology at Allegheny Health Network in Pennsylvania is the lead author of the study. We designed Nerivio with exactly these requirements in mind.”

Side effects 52

Side effects Recruitment Networking Management 52

Pharmaceutical Technology

JANUARY 30, 2023

The FDA approved fewer innovative drugs, New Molecular Entities (NMEs), in 2022 than it did in 2021: only 42 drugs compared to 59 drugs. Increased reluctance to authorise innovative and unproven drugs for use, stemming from the FDA’s experience with Aduhelm, reduced the overall novel approvals in 2022. months longer on the treatment.

Manufacturing 52

Manufacturing FDA Side effects Marketing 52

Silver Line CRM

NOVEMBER 11, 2020

In order to advance the effective delivery of healthcare for individuals, health information systems must work together within and across organizational boundaries. Internally, this means updating legacy systems and combining multiple data sources like ERP and marketing/sales systems needed to be effective.

Marketing 52

Marketing Pharmaceutical Side effects Insurance 52

pharmaphorum

DECEMBER 15, 2022

Back in 2015, the influencer-of-influencers, Kim Kardashian, was slammed for failing to mention the potential side effects of an anti-nausea drug, leading to the US FDA getting involved. Despite the slap on the wrist, the campaign was highly effective and there is no sign of this approach going away.

Media 91

Media Healthcare Healthcare Education 91

Quantified

APRIL 18, 2022

A global head of sales at a pharma company recently told me that “only 15% of our sales calls end in a positive outcome.”. Why is success in pharma sales so hard? Challenge 1: Limited set of marketing and sales tools. The Strategic Importance and Persistence of the Pharma Sales Rep.

Sales 52

Sales Pharma Pharma sales reps Medicine 52

pharmaphorum

OCTOBER 10, 2022

The FDA has approved use of GlaxoSmithKline’s Boostrix (Tdap) vaccine for use during the third trimester of pregnancy, for prevention of pertussis (whooping cough) in infants younger than two months old. This estimate was supported by updated statistical analyses of data published in observational studies, the FDA said.

FDA 52

FDA Side effects Safety Sales 52

pharmaphorum

SEPTEMBER 5, 2022

AstraZeneca’s checkpoint inhibitor Imfinzi has become the first immunotherapy to be approved by the FDA for biliary tract cancer (BTC), a rare and aggressive form of cancer with limited treatment options. billion in sales in the first half of this year.

FDA 52

FDA Side effects Patients Sales 52

pharmaphorum

JULY 19, 2022

China’s Simcere Pharmaceutical has been granted approval in its home market for Cosela, a drug designed to limit the side effects of cancer chemotherapy, partnered with US biotech G1 Therapeutics. Sales remain fairly modest given its single approved use, with the biotech reporting that Cosela made $5.5

Side effects 57

Side effects Marketing Pharmaceutical Patients 57

Medgadget

FEBRUARY 17, 2023

Thanks to kind support from Biomed Israel , the leading international Life Science and HealthTech conference in Israel (see more below), we met with Ronan Castro, the CEO of Human Xtensions at the company’s offices in Netanya, Israel. Human Xtensions chose to proceed with direct sales of its technology in the U.S.

Physicians 80

Physicians Engineering Side effects Leads 80

Silver Line CRM

MARCH 22, 2021

These words have become so overused in the pharmaceutical industry that it’s hard to remember what they really mean: leading with empathy when it comes to serving patients. . What side effects are they talking about? . Your sales team may say, “I want medical data xyz collected right away.” . Patient-focused medicine.

Pharma 52

Pharma Patients Medical Medicine 52

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. million in Q3.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. million in Q3.

Medical 98

Medical Manufacturing Insurance Side effects 98